Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Travera Inc
Endeavor Biomedicines, Inc.
Incyte Corporation
Incyte Corporation
Incyte Corporation
Taproot Health
Symphogen A/S
Xencor, Inc.
Incyte Corporation
AbbVie
Shionogi Inc.
Incyte Corporation
Incyte Corporation
Centre Hospitalier Universitaire de Nice
Masonic Cancer Center, University of Minnesota
Stanford University
Valerio Therapeutics
Valerio Therapeutics
University of Chicago
Mannkind Corporation